Incannex Healthcare Inc. (IXHL): Operating Cash Flow
-$12.87M
Year ended 2026-06-30
-$3.18M
Trailing 12 months to 2026-09-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | -$12.87M | n/m | 2026-09-25, From 2025-07-01 |
| 2025-06-30 | -$12.51M | n/m | 2026-09-25, From 2024-07-01 |
| 2024-06-30 | -$15.85M | n/m | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | -$10.75M | n/a | 2024-09-30, From 2022-07-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | -$12.87M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $2.45M | +109.7% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
Compare IXHL, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗